News

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...
“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...
The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...
Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...
Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...
According to the article, that investor aims to influence the company's choice of a chief executive.